Clinical Trial Update: Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori [Phase 4]

View source ↗

Summary

A Phase 4 trial found that adding bismuth to a rabeprazole-based first-line triple therapy did not improve eradication of Helicobacter pylori.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• Bismuth subsalicylate (bismuth subsalicylate)
• Rabeprazole (rabeprazole)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Helicobacter Pylori Infection | Phase 4 | Status: COMPLETED